i n f l a r x

Loading

Impressum Privacy policy

Contact us

+49 3641 508 180

info@inflarx.de

Address

InflaRx N.V.

Winzerlaer Str. 2, 07745 Jena

Press Release
Home Investors Press Releases Press Release

InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa

Mar 17, 2022

Time to read 4 Minutes
  Download PDF


Back